Should you buy ALNY stock?
Last updated:
Based on market data through , StockInvest.us rates Alnylam Pharmaceuticals (ALNY) as a Sell Candidate with a technical score of -3.65 on its -10 to +10 scale. The rating is unchanged from the previous daily evaluation.
- Sell signal since
- Price since signal Down 23.59%
- 3-month trend forecast Down 11.21%
- Strong return on equity of 93.6%
- High gross margin of 79.7%
- Lower volatility than the market (beta 0.27)
Alnylam Pharmaceuticals stock price down 0.604% on Tuesday
(Market data through Aug 04, 2026)
The Alnylam Pharmaceuticals stock price fell by -0.604% on the last day (Tuesday, 4th Aug 2026) from $220.33 to $219.00. During the last trading day the stock fluctuated 3.49% from a day low at $215.07 to a day high of $222.59. The price has risen in 6 of the last 10 days but is still down by -19.3% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -283 thousand shares and in total, 3 million shares were bought and sold for approximately $664.79 million.
The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $203.58 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -11.21% during the next 3 months and, with a 90% probability hold a price between $180.76 and $276.54 at the end of this 3-month period.
ALNY Signals & Forecast
A buy signal was issued from a pivot bottom point on Thursday, July 30, 2026, and so far it has risen 6.58%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Alnylam Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $243.39 and $280.48. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Support, Risk & Stop-loss for Alnylam Pharmaceuticals stock
On the downside, the stock finds support just below today's level from accumulated volume at $205.52 and $205.48. With no support from accumulated volume below today's level the risk is increased, as a drop below the support at $205.48 may give a huge drop in the stock price.
This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $7.52 between high and low, or 3.49%. For the last week, the stock has had daily average volatility of 6.39%.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (ALNY) For The Upcoming Trading Day Of Wednesday 5th
For the upcoming trading day on Wednesday, 5th we expect Alnylam Pharmaceuticals to open at $218.89, and during the day (based on 14 day Average True Range), to move between $210.86 and $227.14, which gives a possible trading interval of +/-$16.27 (+/-7.72%) up or down from last closing price. If Alnylam Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 7.72% move between the lowest and the highest trading price during the day.
Since the stock is closer to the resistance from accumulated volume at $220.33 (0.61%) than the support at $205.52 (6.16%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.
Is Alnylam Pharmaceuticals stock A Buy?
Alnylam Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Current score:
-3.652
Sell Candidate
Unchanged
Predicted Fair Opening Price
Predicted fair opening price on August 5, 2026 - $218.89 ( 0.0525%).
Want to trade but not sure how?
Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* 
*Your capital is at risk
ALNY Performance
Trading levels for ALNY
Fibonacci Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 226.40 | 3.38% |
| R2 | 223.53 | 2.07% |
| R1 | 221.76 | 1.26% |
| Price | 219.00 | |
| S1 | 216.01 | -1.36% |
| S2 | 214.24 | -2.17% |
| S3 | 211.37 | -3.48% |
Accumulated Volume Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 272.67 | 24.51% |
| R2 | 267.47 | 22.13% |
| R1 | 220.33 | 0.607% |
| Price | 219.00 | |
| S1 | 205.52 | -6.16% |
| S2 | 205.48 | -6.17% |
| S3 | 0 | - |
FAQ
Click here for our free guide on how to buy Alnylam Pharmaceuticals Stock.
Buy ALNY